Harrow, Inc.
HROWHealthcareNASDAQDrug Manufacturers - Specialty & Generic · Last scanned Jun 1, 2026
Scan Results
Daily timeframeHarrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. At a $1.31B market cap, Harrow, Inc. ranks as a small-cap company within healthcare. It operates through Branded and ImprimisRx segments.
Market Cap
$1.31B
Beta
0.34
P/E (TTM)
—
P/E (Fwd)
13.15
EPS (TTM)
$-0.38
EPS (Fwd)
$2.68
ROE
-35.4%
ROA
3.1%
Cash
$96.0M
Total Debt
$300.7M
Free CF
-$5.0M
52W Change
17.4%
Annual Financials
Cash vs Debt
The company holds $96.0M in cash, though total debt stands at $300.7M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. The company is burning cash, with free cash flow at -$5.0M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -35.4% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 3.1% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $88.6M (2022) to $272.3M (2025), reflecting a 207% increase over the period.
With a beta below 0.7, Harrow, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing HROW's risk profile alongside its fundamentals and technical indicators provides a more complete picture.